Cardio-vascular
Refine Search
Pharmaceutical
French pharma major Sanofi is to cut 466 jobs in France and Germany as part of a sharpening of its R&D focus. 20 June 2019
Pharmaceutical
A letter accidentally filed by the US Department of Justice (DoJ) shows that the US Government and Novartis have made "significant progress" settling claims that the Swiss pharma giant paid kickbacks to doctors. 13 June 2019
Pharmaceutical
The Johnson & Johnson subsidiary Janssen has presented important results on Invokana (canagliflozin) at the American Diabetes Association (ADA) meeting. 12 June 2019
Pharmaceutical
Russian financial conglomerate Sistema PJSFC is accelerating expansion in the domestic pharmaceutical business through the acquisition from the investment company Marathon Group of two domestic pharmaceutical companies: Sintez and Biocom, reports The Pharma Letter’s local correspondent. 11 June 2019
Pharmaceutical
Pharma major Sanofi has made presentations at the American Diabetes Association (ADA) meeting that reflect its latest progress in type 1 and 2 of the condition. 10 June 2019
Biotechnology
Adding to a list of significant collaborations with big pharma, USA-based biotech Arvinas has now signed a collaboration with German pharma major Bayer, with the news sending the US firm’s share up more than 8% to $21.66 in early trading today. 4 June 2019
Pharmaceutical
Among noteworthy research news last week was new data for The Medicines Company’s cholesterol lowerer inclisiran showing the drug has dosing advantage. Also, Ocular Therapeutix posted disappointing results for its OTX-TP in glaucoma, but hopes to still get it approved. And Merck & Co’s blockbuster cancer drug Keytruda failed as a tripe-negative breast cancer treatment. Merck was also in the news with its proposed acquisition of biotech firm Peloton Therapeutics, which has a kidney cancer focus. Additionally, German biotech firm Evotec said it is forking out $90 million to buy US firm Just Biotherapeutics. 26 May 2019
Pharmaceutical
At an investor event at its US R&D base, Swiss pharma giant Novartis has reiterated its strategy to “become a leading medicines company powered by advanced therapy platforms and data science.” 23 May 2019
Pharmaceutical
The Medicines Company on Saturday announced interim results from the ongoing ORION-3 open-label extension study (Group 1, n=290) which showed that twice-a-year dosing with inclisiran sodium 300mg resulted in consistent lowering of low density lipoprotein cholesterol (LDL-C) by more than 50% with overall follow-up of up to three years. 20 May 2019
Pharmaceutical
Last week’s news included two interesting, albeit small, acquisitions: Danish CNS specialist Lundbeck announcing it was to purchase Abide Therapeutics; and pharma giant Pfizer intention to buy Swiss biotech Therachon. Pfizer also featured in regulatory news, gaining US Food and Drug Administration approval of its heart disease drug tafamidis. On the research front, Cytokinetics and partner Astellas announced disappointing mid-stage trial results with their amyotrophic lateral sclerosis (ALS) drug reldesemtiv. Japan's Takeda featured in deal-making news, divesting its ophthalmic treatment Xiidra to Novartis for an eye-watering up to $5.3 billion, and the much small deal with Ethicon for TachoSil. 12 May 2019
Pharmaceutical
Industry analyst IQVIA has released its 2019 Medicines Report on US Drug Consumption, showing that in 2018, spending on all US medicines increased 4.5% to $344 billion. 10 May 2019
Pharmaceutical
Pfizer’s Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) look good for exceeding the $1 billion blockbuster threshold. 7 May 2019
Pharmaceutical
Strong sales performance for breast cancer drug Ibrance (palbociclib) and pneumonia vaccine Prevnar (pneumococcal 7-valent conjugate) helped New York’s Pfizer on its way to a 9% bump in profits for the first quarter of 2019. 30 April 2019
Biotechnology
Shares in US biotech Portola Pharmaceuticals closed 3% up on Friday following news that the European Commission (EC) has granted conditional Marketing Authorization for Ondexxya (andexanet alfa). 29 April 2019
Biotechnology
The US Food and Drug Administration has approved Praluent (alirocumab) to reduce the risk of heart attack, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular (CV) disease. 29 April 2019
Pharmaceutical
Carrying on from where the firm left off in 2018, the first quarter of 2019 has been a positive one for Sanofi. 26 April 2019
Pharmaceutical
Quarterly profit at Bayer jumped by nearly 45% as the German life sciences group’s agriculture unit finally started to see some benefit from the takeover of Monsanto. 25 April 2019
Biotechnology
Privately-owned UK-based regenerative medicine company Rexgenero has provided an update on its Phase III studies of REX-001 to treat critical limb ischemia (CLI) in diabetes. 24 April 2019
Pharmaceutical
Shares in Swiss pharma giant Novartis shot up by 2.5% in Wednesday morning’s trading after the company presented its first quarter financial results. 24 April 2019
Pharmaceutical
Shares in US healthcare giant Johnson & Johnson were up by nearly 3% after half-an-hour's trading on Tuesday following the company’s quarterly results presentation. 16 April 2019
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban. 18 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, under development by Ionis Pharmaceuticals. 4 November 2024
Biotechnology
Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. 4 November 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Pharmaceutical
Denmark-based Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. 28 October 2024
Pharmaceutical
Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. 25 October 2024
Pharmaceutical
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Pharmaceutical
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Pharmaceutical
Johnson & Johnson has reported revenue of $22.5 billion for the third quarter of 2024, a 5.2% increase year-over-year. 15 October 2024
Generics
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Pharmaceutical
Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorable court ruling. 8 October 2024
Pharmaceutical
AstraZeneca has entered into an exclusive license agreement with China’s CSPC Pharmaceutical to advance the development of an early stage, novel small molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. 7 October 2024
Pharmaceutical
Privately-held metabolic health specialist Rivus Pharmaceuticals has announced new clinical data from the Phase IIa HuMAIN study of HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) 1 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze